daratumumab,talquetamab,teclistamab,pomalidomide
janssen,genmab
['trimm-2', 'mmsm']
#mmsm #asco23 plasma cell dyscrasia oral session - trimm-2 majority of pts got previous anti-cd38. characteristics, prior use of other bcma targeting agents / car-t exposure etc 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities